Benzinga··Globe NewswireCandel Therapeutics Plans $100M Stock Offering to Fund Cancer Treatment Pipeline
Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.
CADLclinical trialpublic offering